CAGAS
CRBU icon

Capital Advisory Group Advisory Services’s Caribou Biosciences CRBU Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,314
Closed -$19.6K – 36
2025
Q4 		$19.6K Hold
12,314
– – 0.01% 170
2025
Q3 		$28.7K Buy
12,314
+814
+7% +$1.54K 0.01% 179
2025
Q2 		$14.5K Buy
+11,500
New +$11.3K 0.01% 172

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Advisory Group Advisory Services's CRBU Position: Q1 2026 in Review

Capital Advisory Group Advisory Services sold out of Caribou Biosciences (CRBU) in Q1 2026, closing a stake of 12,314 shares — an estimated $19.6K sold.

Capital Advisory Group Advisory Services first reported a position in CRBU in Q2 2025 and held it in 3 quarters. The position peaked at $28.7K in Q3 2025. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Capital Advisory Group Advisory Services reported no remaining Caribou Biosciences position as of Q1 2026 after selling out during the quarter.
  • Capital Advisory Group Advisory Services sold 12,314 Caribou Biosciences shares in Q1 2026, an estimated $19.6K.
  • Capital Advisory Group Advisory Services first reported a position in Caribou Biosciences in Q2 2025 and held it in 3 quarters.
  • Capital Advisory Group Advisory Services's Caribou Biosciences position peaked at $28.7K in Q3 2025.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Capital Advisory Group Advisory Services's 13F filing for Q1 2026, filed 15 Apr 2026.